Canada Nuclear Medicine Market Analysis Report 2024-2030, Featuring Nordion, Lantheus Medical Imaging, Cardinal Health, Jubilant Life Sciences, Isologic Innovative Radiopharmaceuticals & Curium Pharma
24 janv. 2024 05h46 HE
|
Research and Markets
Dublin, Jan. 24, 2024 (GLOBE NEWSWIRE) -- The "Canada Nuclear Medicine Market Size, Share & Trends Analysis Report by Product (Diagnostic, Therapeutic), Application (Oncology, Bone Metastasis,...
Lantheus and POINT Biopharma Announce Positive Topline Results from Pivotal SPLASH Trial in Metastatic Castration-Resistant Prostate Cancer
18 déc. 2023 07h30 HE
|
POINT Biopharma
BEDFORD, Mass. and INDIANAPOLIS, Dec. 18, 2023 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (Lantheus) (NASDAQ: LNTH) and POINT Biopharma Global Inc. (POINT) (NASDAQ: PNT) today announced...
TeleDaaS™ Launches as Premier Provider of Dosimetry as a Service for Clinical Research Organizations
26 nov. 2023 08h00 HE
|
TeleDaas PLLC
TeleDaaS revolutionizes radiopharmaceutical research by delivering highly-scalable, clinical-grade dosimetry to accelerate cancer treatment breakthroughs.
POINT Biopharma Reports Third Quarter 2023 Financial Results and Provides Business Highlights
13 nov. 2023 07h30 HE
|
POINT Biopharma
INDIANAPOLIS, Nov. 13, 2023 (GLOBE NEWSWIRE) -- POINT Biopharma Global Inc. (NASDAQ: PNT) (the “Company” or “POINT”), a company accelerating the discovery, development, and global access to...
Global Radiopharmaceuticals Strategic Analysis Report 2023: Market to Reach $14.3 Billion by 2030 - Emergence of Radiotheranostics as Dual-Functioning Radiopharmaceuticals Bolsters Growth
09 oct. 2023 05h48 HE
|
Research and Markets
Dublin, Oct. 09, 2023 (GLOBE NEWSWIRE) -- The "Radiopharmaceuticals - Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering.Global Radiopharmaceuticals Market...
POINT Biopharma and Athebio Announce Partnership to Develop Designed Ankyrin Repeat Protein Targeted Radioligands
18 sept. 2023 08h00 HE
|
POINT Biopharma
INDIANAPOLIS and SCHLIEREN-ZURICH, Switzerland, Sept. 18, 2023 (GLOBE NEWSWIRE) -- POINT Biopharma Global Inc. (NASDAQ: PNT) (the “Company” or “POINT”), a company accelerating the discovery,...
Radiopharmaceutical Theranostics Market Projected to Reach $3.44 Billion by 2028, Fueled by Growing Cancer Incidence and Personalized Medicine
18 sept. 2023 07h48 HE
|
Research and Markets
Dublin, Sept. 18, 2023 (GLOBE NEWSWIRE) -- The "Radiopharmaceutical Theranostics Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Product Type, Radioisotope, Source, Application,...
POINT Biopharma Reports Second Quarter 2023 Financial Results and Provides Business Highlights
14 août 2023 07h30 HE
|
POINT Biopharma
Enrollment in PNT2002's SPLASH trial is complete and topline data is expected in the fourth quarter of 2023 Next-generation actinium-225 PSMA program PNT2001 phase 1 trial design released; first...
ITM and POINT Biopharma Expand Global Supply Agreement for n.c.a. Lutetium-177
31 juil. 2023 09h00 HE
|
POINT Biopharma
GARCHING / MUNICH, Germany and INDIANAPOLIS, July 31, 2023 (GLOBE NEWSWIRE) -- ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company and POINT Biopharma Global Inc....
POINT Biopharma and AdvanCell to Collaborate in the Development of Lead-212-Labeled Radioligands
26 juin 2023 07h45 HE
|
POINT Biopharma
INDIANAPOLIS and SYDNEY, Australia, June 26, 2023 (GLOBE NEWSWIRE) -- POINT Biopharma Global Inc. (NASDAQ: PNT) (the “Company” or “POINT”), a company accelerating the discovery, development, and...